2nd European Post-Chicago Melanoma Meeting 2012 (more)

My summary conclusions from, among other things, Dr. Agarwala's presentation, management's presence at the Munich conference, data analysis, further information gathering and due diligence:

• Provide a patient enough PV-10, whether through more re-treatments or delivering more drug in general, and MM (cancer) goes away;
• The trial did not sufficiently positively impact several patients because the limited treatment regimen, by trial design, handcuffed PV-10;
• The implication (of the two points above) is that doctors should/must/will try PV-10 first, before either surgery or another non-surgical therapy, to illicit an efficacious result for the patient before determining what other treatment option to utilize;
• There is a clear systemic benefit;
• Overall disease burden is reduced;
• PV-10's response is durable;
• The FDA is helping to get the drug approved; and
• For FDA regulatory purposes only, PV-10 will be used for Stage 3 disease. As soon as PV-10 is approved, the drug will be used for Stage 2 and Stage 4 disease.